Posted by Michael Wonder on 26 Jun 2019
CMS approves Louisiana State Plan Amendment for supplemental rebate agreements using a modified subscription model for hepatitis C therapies in Medicaid
26 June 2019 - State Plan Amendment permits Louisiana to negotiate supplemental drug rebates to assist the state in controlling expenditures for hepatitis C drugs while providing unlimited access to the therapies.
Today the Centers for Medicare and Medicaid Services approved Louisiana’s Medicaid State Plan Amendment (SPA) authorizing the state to negotiate supplemental rebate agreements from prescription drug manufacturers.
The SPA permits the state to negotiate supplemental rebate agreements using a new “modified subscription” model that initially focuses on antiviral agents for hepatitis C and that promotes eliminating the hepatitis C virus statewide.
